Skip to main content

Table 5 Skin and kidney GL-3 content at baseline, week 12 and week 24 (μg/g tissue)

From: Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies

 

Baseline

Week 12

Week 24

Skin

Kidney

Skin

Kidney

Skin

Kidney

FAB CL-202 1

2-0102 2

267

4170

269

3260

-

-

2-0103

337

9510

233

5590

-

-

2-0104

360

9770

309

9210

-

-

2-0202

10.3

4140

11.2

3250

-

-

FAB CL-203 1

3-03012

223

3500

189

-

241

4960

3-0302

230

2100

259

-

349

2860

3-0303

246

623

344

-

300

2850

3-RF01

6.71

1340

9.38

-

10.3

4060

3-RF03

96.1

5300

64.8

-

41.5

3390

  1. 1 Study number.
  2. 2 Subject number.